What is ACXP's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.01B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for ACXP?

P/E (TTM) is n/a and 52-week range is $1.23 to $8.34 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s ACXP figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for ACXP?

The company profile lists net income (TTM) near $-13M, EPS (TTM) near $-3.10 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Acurx Pharmaceuticals Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Staten Island, New York, US, 4.3M shares outstanding, ISIN US00510M2035 when available from company profile and filing metadata.

Acurx Pharmaceuticals Inc

$ACXP

Health Care · Biotechnology

IR Run Scenarios

$1.27

+1.60%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Acurx Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in developing new antibiotics for infections caused by bacteria listed as priority pathogens. The company is headquartered in Staten Island, New York and currently employs 4 full-time employees. The company went IPO on 2021-06-25. The company develops antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its research and development (R&D) pipeline include antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile (C. difficile), methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE), drug-resistant Streptococcus pneumoniae (DRSP) and B. anthracis (anthrax; a Bioterrorism Category A Threat-Level pathogen). Its lead antibiotic candidate, ibezapolstat targets the pol IIIC enzyme.

Employees

Website

www.acurxpharma.com/

IPO

2021-06-25

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)